Otezla (Apremilast)

Apremilast selectively inhibits the enzyme phosphodiesterase‑4 (PDE4), which raises intracellular cAMP levels. Elevated cAMP modulates immune cell signaling, decreasing the production of pro‑inflammatory cytokines such as TNF‑α, IL‑17 and IL‑23, thereby dampening the inflammatory processes underlying psoriasis and psoriatic arthritis.

The dosage of Otezla is individualized by the prescribing clinician. Typically, treatment begins with a titration schedule to reach the target dose of 30 mg taken twice daily, but the exact regimen is determined based on patient tolerance, renal function, and clinical response.

Apremilast is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding; a risk‑benefit assessment should be performed by the healthcare provider.

To request Otezla, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternatives to apremilast are biologic agents such as TNF‑α inhibitors or IL‑17 inhibitors. Unlike biologics, Otezla is an oral small‑molecule therapy, which avoids injections and may have a different safety profile, but biologics often provide higher efficacy in severe disease. Choice depends on disease severity, patient preference, comorbidities and cost considerations.

Store Otezla tablets at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not refrigerate or freeze the tablets.

Otezla is taken orally as a tablet. Patients should swallow each tablet whole with water, typically twice daily after a titration period. It may be taken with or without food, but consistent administration with respect to meals helps maintain steady drug levels.

Serious risks include severe depression, suicidal thoughts or behavior, and rare cases of pancreatitis. Patients should be monitored for mood changes, abdominal pain, and signs of infection. Immediate medical attention is required if any of these serious adverse events occur.

Otezla is contraindicated in individuals with known hypersensitivity to apremilast or any tablet excipients. Caution is advised for patients with severe hepatic impairment, uncontrolled depression, or a history of suicidal ideation. It should also be avoided in patients taking strong CYP3A4 inducers without appropriate dose adjustments.